Cargando…
Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options
After cisplatin-based chemotherapy became the standard treatment for metastatic urothelial cancer (mUC), very little progress has been made in the treatment landscape of this condition until recently. With increased knowledge about the molecular biology of mUC and advances in the field of cancer imm...
Autores principales: | Park, Inkeun, Lee, Jae Lyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373963/ https://www.ncbi.nlm.nih.gov/pubmed/32668516 http://dx.doi.org/10.3904/kjim.2020.204 |
Ejemplares similares
-
Use of Gemcitabine Plus Carboplatin Is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4–5
por: Kim, Hyung-Don, et al.
Publicado: (2021) -
Commentary: Current concepts, recent updates, and future treatment options for Pythium insidiosum keratitis
por: Gurnani, Bharat, et al.
Publicado: (2023) -
Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region
por: Eto, Masatoshi, et al.
Publicado: (2022) -
Current laser therapy options for endoscopic treatment of upper tract urothelial carcinoma
por: Zollinger, Benjamin W., et al.
Publicado: (2023) -
Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
por: Park, Inkeun, et al.
Publicado: (2019)